Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Oracle Corporation — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Oracle Corporation trades at $127.83 (market cap $434.11B). The key difference: Oracle Corporation is far larger — about 48.9× Kymera Therapeutics Inc. Common Stock's market cap, and Oracle Corporation pays a 1.4% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Oracle Corporation for 73 Days on average.
| KYMR | ORCL | |
|---|---|---|
Market Cap | $8.87B | $434.11B |
Volume | 779,107 | 25,917,551 |
Sector | Health | Technology |
52-Week High | $127.31 | $313.00 |
52-Week Low | $55.80 | $114.99 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $8.26B | $557.92B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Oracle (ORCL) trades at $137.40, down 2.92% on the day amid a bearish technical signal, though it has consistently beaten earnings estimates in recent quarters. Revenue grew to $57.40B in 2025 with a net income margin of 26.36%, while analyst consensus remains strongly bullish with a $236.52 price target. Recent news highlights strong AI cloud demand and restructuring efforts to support growth.
The outlook is positive given robust fundamentals and AI-driven revenue acceleration, but risks include high debt levels, competitive pressures, and market volatility. The stock presents a long-term opportunity if execution on AI infrastructure continues, though near-term price weakness reflects investor caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
